Brain Advance Access published online on May 6, 2004
Brain, doi:10.1093/brain/awh156
© 2004 by Guarantors of Brain
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Molecular Medicine & Pathology, Faculty of Medicine and Health Science, University of Auckland, Auckland, New Zealand
* To whom correspondence should be addressed. E-mail: gw.krissansen{at}auckland.ac.nz.
In multiple sclerosis, the immune system attacks the white matter of the brain and spinal cord, leading to disability and/or paralysis. Myelin, oligodendrocytes and neurons are lost due to the release by immune cells of cytotoxic cytokines, autoantibodies and toxic amounts of the excitatory neurotransmitter glutamate. Experimental autoimmune encephalomyelitis (EAE) is an animal model that exhibits the clinical and pathological features of multiple sclerosis. Current therapies that suppress either the inflammation or glutamate excitotoxicity are partially effective when administered at an early stage of EAE, but cannot block advanced disease. In a multi-faceted approach to combat EAE, we blocked inflammation with an anti-MAdCAM-1 (mucosal addressin cell adhesion molecule-1) monoclonal antibody and simultaneously protected oligodendrocytes and neurons against glutamate-mediated damage with the Key Words:
glutamate receptor antagonist; MAdCAM-1 antibody; encephalomyelitis; cell adhesion
Revised January 18, 2004
Accepted January 19, 2004
Article
Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis
Abstract 
-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)/kainate antagonist 2,3-dihydroxy-6-nitro-7- sulfamoylbenzo(f)quinoxaline (NBQX) and the neuroprotector glycine-proline-glutamic acid (GPE; N-terminal tripeptide of insulin-like growth factor). Remarkably, administration at an advanced stage of unremitting EAE of either a combination of NBQX and GPE, or preferably all three latter reagents, resulted in amelioration of disease and repair of the CNS, as assessed by increased oligodendrocyte survival and remyelination, and corresponding decreased paralysis, inflammation, CNS apoptosis and axonal damage. Each treatment reduced the expression of nitric oxide and a large panel of proinflammatory and immunoregulatory cytokines, in particular IL-6 which plays a critical role in mediating EAE. Mice displayed discernible improvements in all physical features examined. Disease was suppressed for 5 weeks, but relapsed when treatment was suspended, suggesting treatment must be maintained to be effective. The above approaches, which allow CNS repair by inhibiting inflammation and/or simultaneously protect neurons and oligodendrocytes from damage, could thus be effective therapies for multiple sclerosis.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Centonze, L. Muzio, S. Rossi, F. Cavasinni, V. De Chiara, A. Bergami, A. Musella, M. D'Amelio, V. Cavallucci, A. Martorana, et al. Inflammation Triggers Synaptic Alteration and Degeneration in Experimental Autoimmune Encephalomyelitis J. Neurosci., March 18, 2009; 29(11): 3442 - 3452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.E. Gonsette Review: Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis? Multiple Sclerosis, January 1, 2008; 14(1): 22 - 34. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Tiwari-Woodruff, L. B. J. Morales, R. Lee, and R. R. Voskuhl Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER){alpha} and ERbeta ligand treatment PNAS, September 11, 2007; 104(37): 14813 - 14818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Chitnis, J. Imitola, Y. Wang, W. Elyaman, P. Chawla, M. Sharuk, K. Raddassi, R. T. Bronson, and S. J. Khoury Elevated Neuronal Expression of CD200 Protects Wlds Mice from Inflammation-Mediated Neurodegeneration Am. J. Pathol., May 1, 2007; 170(5): 1695 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Lopatinskaya, J Zwemmer, B Uitdehaag, K Lucas, C Polman, and L Nagelkerken Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years Multiple Sclerosis, November 1, 2006; 12(6): 704 - 709. [Abstract] [PDF]
|
|
|
|
 |
|
 R. M. Sappington, M. Chan, and D. J. Calkins Interleukin-6 protects retinal ganglion cells from pressure-induced death. Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 2932 - 2942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Bannerman, A. Hahn, S. Ramirez, M. Morley, C. Bonnemann, S. Yu, G.-X. Zhang, A. Rostami, and D. Pleasure Motor neuron pathology in experimental autoimmune encephalomyelitis: studies in THY1-YFP transgenic mice Brain, August 1, 2005; 128(8): 1877 - 1886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Alexander and T. Ando Density-dependent control of MAdCAM-1 and chronic inflammation. Focus on "Mechanisms of MAdCAM-1 gene expression in human intestinal microvascular endothelial cells" Am J Physiol Cell Physiol, February 1, 2005; 288(2): C243 - C244. [Full Text] [PDF]
|
|
|
|
|
|
R. Diem, M. B. Sattler, D. Merkler, I. Demmer, K. Maier, C. Stadelmann, H. Ehrenreich, and M. Bahr Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis Brain, February 1, 2005; 128(2): 375 - 385. [Abstract] [Full Text] [PDF]
|
|